Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator
LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls™ suite of products, is pleased to announce the filing of additional patents with the United States Patent and Trade Office (USPTO) which it believes further protects the Company's innovations in the commercialization of a broad array of functional mushroom ingredients for the rapidly growing consumer and enterprise markets.
The three additional patents that have been filed are as follows:
'We are blazing an innovative trail, harnessing the magic of the mushroom and bringing it everywhere from the comfort of the home to commercial kitchens who want predictable, scalable mushroom ingredients in their offering,' stated Stone Douglass, CEO, Hypha Labs. 'These patents, which we have briefly detailed herein, affirm our strong position in the space as we look to our product roll-out on the not-so-far horizon, protecting our mass production plans, A.I. integrations, and maybe most importantly our Replaceable Sterile Cartridge System which to the keen eye should make clear our evergreen relationship with the customer vis-à-vis the razor/razor blade model fully in play.'
Hypha Labs remains committed to advancing the science of mushroom cultivation equipment and genetic research to accommodate these advances. The integration of its new HPLC machine and the variable loop autosampler upgrade marks a significant milestone in Hypha's journey to deliver innovative solutions and insights to our customers, clients and partners.
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as 'estimate,' 'project,' 'predict,' 'will,' 'would,' 'should,' 'could,' 'may,' 'might,' 'anticipate,' 'plan,' 'intend,' 'believe,' 'expect,' 'aim,' 'goal,' 'target,' 'objective,' 'likely' or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity MediaInc.
(888) 216-3595
[email protected]
SOURCE: Hypha Labs, Inc.
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@
Yahoo
an hour ago
- Yahoo
Studio 17 Spotlights Kern County SHRM Annual Conference
Presented by: Kern County SHRM On today's Studio 17, Kait Hill spoke with with Jackie Andrade, Conference Director, and Sky Newton, Conference Vice Chair, from Kern County SHRM to discuss their upcoming annual conference. Kern County SHRM plays a key role in connecting the local business community through leadership, professional development, and networking. With a long-standing presence in the region, Kern County SHRM's conference promises powerful keynote speakers and fresh topics that reflect the evolving workplace. The event welcomes not only HR professionals but anyone interested in career growth and leadership skills. Attendees can look forward to dynamic sessions and a vibrant atmosphere that encourages learning and connection. For those wanting to get involved year-round or register for the conference, more information is available on the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
City approves task order for Lynn Haven stormwater project
LYNN HAVEN, Fla. (WMBB) – Lynn Haven is making progress on stormwater drainage improvements. It's been a problem for decades, but worsened after Hurricane Michael, causing flooding even during moderate rains. City officials signed a task order today to finish the remainder of the project. In 2022, Lynn Haven received a $1 million legislative appropriation to address long-standing stormwater issues. With clogged pipes and blocked outflows choked by grass and sediment, flooding has been a persistent problem in the community for decades. Dolphin transport underway at Gulf World 'We want to prevent any structural flooding. We want to get water from standing in roadways so emergency vehicles can pass. And of course, you know, our residents to walk down the road if needed in an emergency or be able to leave their home without flooding their cars out,' said Public Works Director Chris Lightfoot. The city divided the project into phases, prioritizing repairs that didn't require permits from the Army Corps of Engineers or the Florida Department of Environmental Protection. That allowed crews to start clearing and maintaining some systems immediately. Some of the work has occurred along 7th Street and Kentucky Avenue, and 13th and Missouri Avenue. Panama City approves new areas for golf cart safety 'The outfall construction that we're doing is basically excavating and armor forming the outfalls to provide a clear flow for the stormwater to get out. Currently, it's grass and sediment that builds up and constantly having to be maintained. It's difficult to maintain because they stay so wet. So we will just get these cleaned out. They will be a permanent structure, and they can flow freely,' Lightfoot added. The city has used about $700,000 so far. The remaining $300,000 will go to trouble spots like East 2nd Street and Illinois off 10th Street. 'That it will allow storm water to recede faster and hopefully not be in our streets and roadways,' Mayor Jesse Nelson said. The entire project is expected to take about 120 days to complete. That work will go out to bid in the near future. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
